Ben Steinmetz comes to Panavance with a wealth of pharmaceutical launch experience and oncology expertise. Since 2018, he has been the Managing Director of the Steinmetz Advisory Group, specializing in the development and commercialization of oncology products. He serves as acting Chief Commercial Officer, as he is doing for Panavance, for pre-commercial stage oncology companies and is engaged with clients on projects ranging from development & commercial strategy for IND stage assets to market access strategy and execution for phase III and launch-stage products.

In 2015, Ben joined Churchill Pharmaceuticals as SVP Commercial, leading the launch of a new oral anticancer agent in a >$4 billion market. He established the product launch plan reflecting the competitive set, the differential timing of commercial and government payer reviews, the critical differences between physician dispensing and specialty pharmacy models, evolving US political and reimbursement environment, and the need to effectively deploy valuable human and monetary resources. Prior to Churchill, he was VP Reimbursement and Patient Access for GlaxoSmithKline and VP Policy and Payer Insight, Oncology/Biopharmaceuticals, in GSK’s US managed care division. Ben was VP Global Commercial Strategy, Oncology, and accountable for global product management, scientific communications, and health outcomes for GSK’s oncology portfolio. Product responsibilities included therapeutic and supportive care products such as Votrient®, Tykerb®, Arzerra®, Arranon®, and Promacta® as well as many discovery and development stage products. Before joining GSK, he worked in senior roles at Exocell, a development stage biotechnology company, and Eastman Pharmaceuticals/Sterling Winthrop (now Sanofi).